Detalhe da pesquisa
1.
A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
Eur J Nucl Med Mol Imaging
; 44(8): 1319-1327, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28421240
2.
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
Oncology
; 91(5): 267-273, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27544669
3.
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Cancer
; 120(7): 968-75, 2014 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24382803
4.
Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
Lancet Oncol
; 13(5): 509-17, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22326922
5.
A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.
Eur J Cancer
; 90: 1-9, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29268139
6.
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
Med Oncol
; 28(4): 1136-9, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-20567941